C8 MediSensors, a US-based diabetes treatment company backed by US-based conglomerate General Electric, has raised $19m. The funding will help C8 MediSensors launch in Europe. C8 MediSensors said its “leading investors” participated in the round. C8 MediSensors uses light, in a process called Raman spectroscopy, to allow diabetics to measure glucose in a monitor. C8 Medisensors secured $24m in its series C funding last year investors including General Electric’s GE Capital financial services division and its GE Healthcare division, which made the investment through its Healthymagination fund. C8 stated that GE joined existing investors in the round, but did not disclose the identity of the backers. C8 had raised about $74.5m, according to Global Corporate Venturing estimates from the company’s Securities and Exchange Commission filings at the time of this C round.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?